Immuno Gen, Inc. IMGN
We take great care to ensure that the data presented and summarized in this overview for ImmunoGen, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IMGN
View all-
Pictet Asset Management Sa Geneva 73, V8721KShares$00.02% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC416KShares$03.65% of portfolio
-
Health Cor Management, L.P. New York, NY150KShares$00.7% of portfolio
-
Kellner Capital, LLC New York, NY69.2KShares$03.7% of portfolio
-
Leo Brokerage, LLC25KShares$00.05% of portfolio
-
Baystate Wealth Management LLC24.1KShares$00.05% of portfolio
-
Caitlin John, LLC Brighton, MI1.86KShares$00.04% of portfolio
-
Coppell Advisory Solutions LLC Coppell, TX1.07KShares$00.01% of portfolio
-
Ifp Advisors, Inc830Shares$00.0% of portfolio
-
Hm Payson & CO Portland, ME810Shares$00.0% of portfolio
Latest Institutional Activity in IMGN
Top Purchases
Top Sells
About IMGN
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Insider Transactions at IMGN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 12
2024
|
Richard John Wallace Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,000
-100.0%
|
-
|
|
Feb 12
2024
|
Mark J Enyedy CHIEF EXECUTIVE OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
584,397
-100.0%
|
-
|
|
Feb 12
2024
|
Helen M. Thackray Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,074
-100.0%
|
-
|
|
Feb 12
2024
|
Dean J Mitchell Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
103,000
-100.0%
|
-
|
|
Feb 12
2024
|
Theresa Wingrove SVP OF REGULATORY AFFAIRS |
SELL
Sale (or disposition) back to the issuer
|
Direct |
21,039
-100.0%
|
-
|
|
Feb 12
2024
|
Stuart A Arbuckle Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,381
-100.0%
|
-
|
|
Feb 12
2024
|
Mark Alan Goldberg Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
60,720
-100.0%
|
-
|
|
Feb 12
2024
|
Renee Lentini VP & PRIN ACCTG OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
14,723
-100.0%
|
-
|
|
Feb 12
2024
|
Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
73,274
-100.0%
|
-
|
|
Feb 12
2024
|
Michael Vasconcelles EVP R&D & MEDICAL AFFAIRS |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,327
-100.0%
|
-
|
|
Feb 12
2024
|
Daniel Char SVP & CHIEF LEGAL OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,000
-100.0%
|
-
|
|
Feb 05
2024
|
Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
4,583
-5.89%
|
$132,907
$29.3 P/Share
|
|
Feb 05
2024
|
Renee Lentini VP & PRIN ACCTG OFFICER |
SELL
Open market or private sale
|
Direct |
2,631
-15.16%
|
$76,299
$29.3 P/Share
|
|
Feb 05
2024
|
Mark J Enyedy CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
20,107
-3.33%
|
$583,103
$29.28 P/Share
|
|
Feb 05
2024
|
Theresa Wingrove SVP OF REGULATORY AFFAIRS |
SELL
Open market or private sale
|
Direct |
12,027
-36.37%
|
$348,783
$29.3 P/Share
|
|
Feb 02
2024
|
Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
14,350
+15.56%
|
-
|
|
Feb 02
2024
|
Renee Lentini VP & PRIN ACCTG OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
8,435
+32.71%
|
-
|
|
Feb 02
2024
|
Mark J Enyedy CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
51,234
+7.81%
|
-
|
|
Feb 02
2024
|
Theresa Wingrove SVP OF REGULATORY AFFAIRS |
BUY
Exercise of conversion of derivative security
|
Direct |
29,640
+47.27%
|
-
|
|
Jan 16
2024
|
Theresa Wingrove SVP OF REGULATORY AFFAIRS |
SELL
Open market or private sale
|
Direct |
187,667
-98.21%
|
$5,442,343
$29.64 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 26.7K shares |
|---|---|
| Exercise of conversion of derivative security | 4.97M shares |
| Sale (or disposition) back to the issuer | 878K shares |
|---|---|
| Open market or private sale | 4.79M shares |
| Exercise of conversion of derivative security | 30K shares |